Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable, advanced melanoma.
OncoSec’s lead product, Tavo, uses electroporation to deliver IL-12 directly into a patient’s tumor, triggering an immune response.
Get the full story at our sister site, Drug Delivery Business News.
The post OncoSec shares fall on preliminary data from skin cancer trial appeared first on MassDevice.